dc.contributor.author | Reck, M | |
dc.contributor.author | Kerr, KM | |
dc.contributor.author | Grohé, C | |
dc.contributor.author | Manegold, C | |
dc.contributor.author | Pavlakis, N | |
dc.contributor.author | Paz-Ares, L | |
dc.contributor.author | Huber, RM | |
dc.contributor.author | Popat, S | |
dc.contributor.author | Thatcher, N | |
dc.contributor.author | Park, K | |
dc.contributor.author | Hilberg, F | |
dc.contributor.author | Barrueco, J | |
dc.contributor.author | Kaiser, R | |
dc.date.accessioned | 2020-06-09T12:02:50Z | |
dc.date.issued | 2019-04 | |
dc.identifier.citation | Future oncology (London, England), 2019, 15 (12), pp. 1363 - 1383 | |
dc.identifier.issn | 1479-6694 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/3716 | |
dc.identifier.eissn | 1744-8301 | |
dc.identifier.doi | 10.2217/fon-2018-0948 | |
dc.description.abstract | A substantial proportion of patients with nononcogene-addicted non-small-cell lung cancer (NSCLC) has 'aggressive disease', as reflected in short time to progression or lack of disease control with initial platinum-based chemotherapy. Recently, clinical correlates of aggressive disease behavior during first-line therapy have been shown to predict greater benefit from addition of nintedanib to second-line docetaxel in adenocarcinoma NSCLC. Positive predictive effects of aggressive disease have since been reported with other anti-angiogenic agents (ramucirumab and bevacizumab), while such features may negatively impact on outcomes with nivolumab in nonsquamous NSCLC with low PD-L1 expression. Based on a review of the clinical data, we recommend aggressive nonsquamous NSCLC should be defined by progression within <6-9 months of first-line treatment initiation. | |
dc.format | Print-Electronic | |
dc.format.extent | 1363 - 1383 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0 | |
dc.subject | Lung | |
dc.subject | Humans | |
dc.subject | Carcinoma, Non-Small-Cell Lung | |
dc.subject | Lung Neoplasms | |
dc.subject | Disease Progression | |
dc.subject | Indoles | |
dc.subject | Antineoplastic Combined Chemotherapy Protocols | |
dc.subject | Antibodies, Monoclonal | |
dc.subject | Disease-Free Survival | |
dc.subject | Patient Selection | |
dc.subject | Time Factors | |
dc.subject | Antibodies, Monoclonal, Humanized | |
dc.subject | Bevacizumab | |
dc.subject | Docetaxel | |
dc.title | Defining aggressive or early progressing nononcogene-addicted non-small-cell lung cancer: a separate disease entity? | |
dc.type | Journal Article | |
rioxxterms.versionofrecord | 10.2217/fon-2018-0948 | |
rioxxterms.licenseref.uri | https://creativecommons.org/licenses/by/4.0 | |
rioxxterms.licenseref.startdate | 2019-04 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | Future oncology (London, England) | |
pubs.issue | 12 | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Thoracic Oncology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Thoracic Oncology/Thoracic Oncology (hon.) | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Thoracic Oncology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Thoracic Oncology/Thoracic Oncology (hon.) | |
pubs.publication-status | Published | |
pubs.volume | 15 | |
pubs.embargo.terms | Not known | |
icr.researchteam | Thoracic Oncology | en_US |
dc.contributor.icrauthor | Popat, Sanjay | |